A Multi-Arm Two-Stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trials.
A Multi-Arm Two-Stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trials. Contemp Clin Trials. 2023 09; 132:107278.
PMID: 37419308
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma.
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma. Commun Med (Lond). 2023 Mar 03; 3(1):35.
PMID: 36869161
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease.
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Transl Stroke Res. 2023 08; 14(4):513-529.
PMID: 35715588
Practical Impact of Modern Dose-Finding Designs When Compared With the 3 + 3 Design: An Editorial.
Practical Impact of Modern Dose-Finding Designs When Compared With the 3 + 3 Design: An Editorial. JCO Precis Oncol. 2021 11; 5:1584-1587.
PMID: 34994645
RoBoT: a robust Bayesian hypothesis testing method for basket trials.
RoBoT: a robust Bayesian hypothesis testing method for basket trials. Biostatistics. 2021 10 13; 22(4):897-912.
PMID: 32061093
Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage.
Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage. J Cereb Blood Flow Metab. 2021 11; 41(11):2944-2956.
PMID: 34039038
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 02 16; 88(3):686-697.
PMID: 33469662
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
PMID: 33234578
RoBoT: a robust Bayesian hypothesis testing method for basket trials.
Zhou T, Ji Y. RoBoT: a robust Bayesian hypothesis testing method for basket trials. Biostatistics. 2020 Feb 15.
PMID: 32061093
The evolutionary history of 2,658 cancers.
The evolutionary history of 2,658 cancers. Nature. 2020 02; 578(7793):122-128.
PMID: 32025013
Elected Fellow
The American Statistical Association
2020
Mitchell Prize
ISBA
2015